 |
Drug Delivery Report: Home
|
 |
 |
|
 |
|
Welcome to drugdeliveryreport.com!
Established for over 13 years, the Drug Delivery Report is relied upon within the
industry as the main method of independently assessing drug delivery partners to enable drug delivery deal making.
drugdeliveryreport.com has been developed to ensure that you can access up-to-the-minute drug delivery deal making opportunities
as well as key facts and trends affecting the drug delivery market.
Read more...
Market news and trends
In the October to December 2007 period, 92 deals involving drug delivery took place. These included two financially significant deals: between XenoPort and Xanodyne Pharmaceuticals, and between Endo Pharmaceuticals Holdings and Alexza Pharmaceuticals. Licensing deals were the most prevalent deal types, followed by co-development agreements. One manufacturing agreement also took place during this period, between Mumbai-based Cipla and US-based Akorn. Read more...
|
|
 |
|
 |
|
|
|
|
Featured article - A Transforming Deal Combining Biologics with Drug Delivery
Business models tend to underestimate the value of drug delivery for enhancing medical innovation. Halozyme and Roche hope to change this perception, as they collaborate to apply Halozyme's novel Enhanze™ drug delivery technology to Roche's leading portfolio of biologics. In this article, Louk Pechtold from F. Hoffmann-La Roche and Michael Haller from Halozyme Therapeutics outline the strategy and creativity of the business model, and its potential implications
Read more...
Featured company profiles
Abraxis BioScience, Inc,
Bang & Olufsen Medicom,
Emergent Technologies, Inc.,
Mayne Pharma International,
LiPlasome Pharma AS,
Phares Drug Delivery AG,
Ypsomed AG,
|
|
|
|
|
|
|
|
